Liminatus Pharma Completes InnocsAI Acquisition, Issues Highly Dilutive Convertible Preferred Stock

summarizeSummary

Liminatus Pharma has completed its acquisition of InnocsAI LLC, issuing common stock and a substantial amount of non-voting convertible preferred stock that could lead to over 2,800% dilution upon full conversion.

check_boxKey Events · M&A and Partnerships · LIMN

• Acquisition Consummated

  The merger with InnocsAI LLC was completed on July 2, 2026, following an amended agreement that allows closing prior to full stockholder approval for the entire consideration.

• Dilutive Share Issuance

  The company issued 11,188,729 common shares and 158,881.1271 shares of newly designated Series A Non-Voting Convertible Preferred Stock as merger consideration to InnocsAI's former members.

• Massive Potential Dilution

  Each Series A Preferred Stock share is convertible into 10,000 common shares, potentially adding over 1.58 billion common shares, representing over 2,800% dilution to pre-merger outstanding shares.

• Deferred Shareholder Vote

  Conversion of the preferred stock requires future shareholder approval, allowing the merger to close without immediate full dilution, but creating a significant overhang.

auto_awesomeAnalysis · LIMN · Life Sciences

This filing confirms the completion of Liminatus Pharma's acquisition of InnocsAI LLC on July 2, 2026, a critical event for the nano-cap company. The deal structure involved issuing 11.19 million common shares immediately and 158,881 shares of Series A Non-Voting Convertible Preferred Stock. Each preferred share is convertible into 10,000 common shares, meaning the preferred stock alone could add over 1.58 billion common shares to the outstanding count, representing over 2,800% potential dilution to pre-merger outstanding shares. This massive dilution, while deferred for a full shareholder vote on preferred stock conversion, is a significant concern for existing shareholders, especially given the company's existing 'going concern' warning and recent Nasdaq delisting notice. The company will need to secure shareholder approval for the preferred stock conversion and navigate its financial distress while integrating the new business, all while a reverse stock split is also pending.